A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

被引:40
|
作者
Zhong, Runbo [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Dis, Shanghai 200030, Peoples R China
关键词
Chemoimmunotherapy; Dendritic cell; Cytokine-induced killer cell; Non-small cell lung cancer;
D O I
10.1007/s13277-013-1132-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB-IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine-platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P = 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35-9.24) to 7.3 months (95 % CI, 5.45-6.95; P = 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.
引用
收藏
页码:987 / 994
页数:8
相关论文
共 50 条
  • [1] Prospective Study of Chemotherapy in Combination with Cytokine-induced Killer Cells in Patients Suffering from Advanced Non-small Cell Lung Cancer
    Wu, Changping
    Jiang, Jingting
    Shi, Liangrong
    Xu, Ning
    ANTICANCER RESEARCH, 2008, 28 (6B) : 3997 - 4002
  • [2] Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
    Runbo Zhong
    Jiajun Teng
    Baohui Han
    Hua Zhong
    Cancer Immunology, Immunotherapy, 2011, 60 : 1497 - 1502
  • [3] Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
    Zhong, Runbo
    Teng, Jiajun
    Han, Baohui
    Zhong, Hua
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (10) : 1497 - 1502
  • [4] Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer
    Shi, Sheng Bin
    Ma, Ting Hang
    Li, Chun Hua
    Tang, Xiao Yong
    TUMORI, 2012, 98 (03) : 314 - 319
  • [5] Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study
    Lin, Tao
    Song, Chun
    Chuo, Dong-yu
    Zhang, Hao
    Zhao, Jian
    TUMOR BIOLOGY, 2016, 37 (04) : 4367 - 4372
  • [6] Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer
    Zhang, Lihong
    Yang, Xuejing
    Sun, Zhen
    Li, Jiali
    Zhu, Hui
    Li, Jing
    Pang, Yan
    ONCOLOGY LETTERS, 2016, 11 (04) : 2605 - 2610
  • [7] Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer
    Tian, Lin
    Wang, Wei
    Yu, Bin
    Zhang, Guoxia
    JOURNAL OF BUON, 2020, 25 (05): : 2364 - 2370
  • [8] Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer
    Yu, Baodan
    Wang, Junli
    He, Chen
    Wang, Wei
    Tang, Jianli
    Zheng, Runhui
    Zhou, Chengzhi
    Zhang, Huanhuan
    Fu, Zhiping
    Li, Qiasheng
    Xu, Jun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (01) : 831 - 840
  • [9] The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV Non-small cell lung cancer
    Li, Liuning
    Liu, Jiaying
    Chai, Xiaoshu
    Zhang, Liwen
    Chen, Zhijian
    He, Chunxia
    Hong, Hongxi
    2014 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE (BIBM), 2014,
  • [10] A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer
    Zhu, X. P.
    Xu, Y. H.
    Zhou, J.
    Pan, X. F.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03) : 10228 - 10235